Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

Apoptosis; Aurora kinases; Caspases; Cell cycle; MEK/ERK/mTORC1; PI3K/Akt/mTORC2; Polo-like kinases; T-ALL; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aza Compounds; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Coculture Techniques; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Humans; Indoles; Jurkat Cells; Mice; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Drug Design; Molecular Targeted Therapy; Cell Biology; Molecular Biology; Developmental Biology